These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


1323 related items for PubMed ID: 31265100

  • 1. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
    Schnitzer TJ, Easton R, Pang S, Levinson DJ, Pixton G, Viktrup L, Davignon I, Brown MT, West CR, Verburg KM.
    JAMA; 2019 Jul 02; 322(1):37-48. PubMed ID: 31265100
    [Abstract] [Full Text] [Related]

  • 2. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
    Berenbaum F, Blanco FJ, Guermazi A, Miki K, Yamabe T, Viktrup L, Junor R, Carey W, Brown MT, West CR, Verburg KM.
    Ann Rheum Dis; 2020 Jun 02; 79(6):800-810. PubMed ID: 32234715
    [Abstract] [Full Text] [Related]

  • 3. Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial.
    Hochberg MC, Carrino JA, Schnitzer TJ, Guermazi A, Walsh DA, White A, Nakajo S, Fountaine RJ, Hickman A, Pixton G, Viktrup L, Brown MT, West CR, Verburg KM.
    Arthritis Rheumatol; 2021 Jul 02; 73(7):1167-1177. PubMed ID: 33538113
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.
    Schnitzer TJ, Ekman EF, Spierings EL, Greenberg HS, Smith MD, Brown MT, West CR, Verburg KM.
    Ann Rheum Dis; 2015 Jun 02; 74(6):1202-11. PubMed ID: 24625625
    [Abstract] [Full Text] [Related]

  • 5. Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration study.
    Schnitzer TJ, Khan A, Bessette L, Davignon I, Brown MT, Pixton G, Prucka WR, Tive L, Viktrup L, West CR.
    Semin Arthritis Rheum; 2020 Jun 02; 50(3):387-393. PubMed ID: 32252976
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
    Balanescu AR, Feist E, Wolfram G, Davignon I, Smith MD, Brown MT, West CR.
    Ann Rheum Dis; 2014 Sep 02; 73(9):1665-72. PubMed ID: 23852695
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen.
    Ekman EF, Gimbel JS, Bello AE, Smith MD, Keller DS, Annis KM, Brown MT, West CR, Verburg KM.
    J Rheumatol; 2014 Nov 02; 41(11):2249-59. PubMed ID: 25274899
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A, Ma C, Ahdieh H, Galer BS.
    Clin Ther; 2006 Mar 02; 28(3):352-64. PubMed ID: 16750450
    [Abstract] [Full Text] [Related]

  • 15. Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
    Berenbaum F, Langford R, Perrot S, Miki K, Blanco FJ, Yamabe T, Isogawa N, Junor R, Carey W, Viktrup L, West CR, Brown MT, Verburg KM.
    Eur J Pain; 2021 Aug 02; 25(7):1525-1539. PubMed ID: 33728717
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials.
    Berenbaum F, Schnitzer T, Kivitz A, Viktrup L, Johnston E, Yang R, Whalen E, Tive L, Semel D.
    Int J Clin Pract; 2021 Dec 02; 75(12):e14975. PubMed ID: 34626502
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies.
    Kelly KM, Sanga P, Zaki N, Wang S, Haeussler J, Louie J, Thipphawong J.
    Curr Med Res Opin; 2019 Dec 02; 35(12):2117-2127. PubMed ID: 31387410
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 67.